1. Home
  2. IVVD vs BRID Comparison

IVVD vs BRID Comparison

Compare IVVD & BRID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IVVD
  • BRID
  • Stock Information
  • Founded
  • IVVD 2020
  • BRID 1932
  • Country
  • IVVD United States
  • BRID United States
  • Employees
  • IVVD N/A
  • BRID N/A
  • Industry
  • IVVD Biotechnology: Pharmaceutical Preparations
  • BRID Specialty Foods
  • Sector
  • IVVD Health Care
  • BRID Consumer Staples
  • Exchange
  • IVVD Nasdaq
  • BRID Nasdaq
  • Market Cap
  • IVVD 63.4M
  • BRID 70.3M
  • IPO Year
  • IVVD 2021
  • BRID N/A
  • Fundamental
  • Price
  • IVVD $1.43
  • BRID $7.67
  • Analyst Decision
  • IVVD Strong Buy
  • BRID
  • Analyst Count
  • IVVD 4
  • BRID 0
  • Target Price
  • IVVD $3.64
  • BRID N/A
  • AVG Volume (30 Days)
  • IVVD 15.0M
  • BRID 4.9K
  • Earning Date
  • IVVD 11-13-2025
  • BRID 08-22-2025
  • Dividend Yield
  • IVVD N/A
  • BRID N/A
  • EPS Growth
  • IVVD N/A
  • BRID N/A
  • EPS
  • IVVD N/A
  • BRID N/A
  • Revenue
  • IVVD $46,210,000.00
  • BRID $224,673,000.00
  • Revenue This Year
  • IVVD $385.94
  • BRID N/A
  • Revenue Next Year
  • IVVD $62.62
  • BRID N/A
  • P/E Ratio
  • IVVD N/A
  • BRID N/A
  • Revenue Growth
  • IVVD 1941.08
  • BRID N/A
  • 52 Week Low
  • IVVD $0.35
  • BRID $7.35
  • 52 Week High
  • IVVD $2.74
  • BRID $10.83
  • Technical
  • Relative Strength Index (RSI)
  • IVVD 72.86
  • BRID 47.68
  • Support Level
  • IVVD $0.96
  • BRID $7.79
  • Resistance Level
  • IVVD $1.45
  • BRID $8.15
  • Average True Range (ATR)
  • IVVD 0.19
  • BRID 0.27
  • MACD
  • IVVD 0.05
  • BRID 0.03
  • Stochastic Oscillator
  • IVVD 97.86
  • BRID 39.24

About IVVD Invivyd Inc.

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

About BRID Bridgford Foods Corporation

Bridgford Foods Corp manufactures, markets, and distributes frozen and snack food products in the United States. The business segments are; the processing and distribution of frozen products, and the processing and distribution of snack food products. Its product offerings include meat snacks, breads and rolls, biscuits, and ready-to-eat sandwiches among others. The company offers frozen food products to the foodservice and retail customers through wholesalers, cooperatives, and distributors; and snack food items to supermarkets, and mass merchandise and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. A majority of the company's revenue is derived from the snack food products segment.

Share on Social Networks: